Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of sterol and pharmaceutically acceptable salts thereof in preparation of medicine for resisting hepatitis B virus

A hepatitis B virus and sterol technology, applied in the direction of antiviral agents, drug combinations, steroids, etc., can solve the problems of long course of treatment, easy accumulation of drug resistance, and large side effects, and achieve good anti-hepatitis B virus. Effect

Pending Publication Date: 2020-06-19
HUAQIAO UNIVERSITY
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Currently, there are two types of drugs clinically used in the treatment of chronic hepatitis B virus: one is immunomodulators, which have a low response rate and large side effects; the other is nucleotide analogs, which are prone to accumulate drug resistance and have a long course of treatment. Lifelong treatment is required, so the development of new safe and effective anti-HBV drugs is a top priority

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of sterol and pharmaceutically acceptable salts thereof in preparation of medicine for resisting hepatitis B virus
  • Application of sterol and pharmaceutically acceptable salts thereof in preparation of medicine for resisting hepatitis B virus
  • Application of sterol and pharmaceutically acceptable salts thereof in preparation of medicine for resisting hepatitis B virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Extraction and separation of embodiment 1 sterol

[0024] 1. Preparation of snail extract:

[0025] Take 25kg of fresh sea snail samples, wash and remove the sediment, heat in boiling water for 3-5 minutes, remove the shell, freeze-dry the remaining soft tissue, grind the powder with a high-speed pulverizer, and put the powder in a 1000mL round bottom flask in batches, Add appropriate amount of 95% ethanol to reflux for extraction. Four extractions were performed, with each extraction taking 1 to 2 hours. Concentrate all the extracts by rotary evaporation, place them in a freeze dryer overnight after concentration, and obtain 95% ethanol extract, weighing 381 g.

[0026] The above-mentioned 95% ethanol extract is sequentially extracted with petroleum ether, dichloromethane, ethyl acetate and n-butanol, the extracted solution is combined and concentrated, that is, the sample is roughly divided into five phases and weighed, wherein the petroleum ether extract (APE) is ...

Embodiment 2

[0031] Embodiment 2 sterol in vitro activity screening

[0032] Hepatitis B virus antigen (HBsAg) and hepatitis B virus e antigen (HBeAg) are clinically important indicators for judging HBV infection. Hepatitis B surface antigen (HBsAg) is the coat protein of HBV. It is antigenic and not infectious, but its appearance is often accompanied by the presence of HBV, so it is a sign of HBV infection. HBeAg is the core internal component of the virus, and it is considered as a sign of virus replication in virus serological detection, indicating that there is progressive damage and high infectivity in liver cells. HBV DNA is HBV deoxyribonucleic acid, which is also the core part of the virus. It is the gold indicator for judging the replication of the virus. The quantitative examination of HBV DNA is the most direct indicator for detecting HBV infection. Clinically, quantitative detection of HBV content in the blood of hepatitis B patients can determine the infection status of patie...

Embodiment approach

[0037] a. Compound solution preparation: Dissolve 8.0 mg of compounds 1 to 3 in 500 μL DMSO, and make 4 gradient double dilutions in DMSO.

[0038] b. Cell plate: Dilute the HepG2.2.15 cells in the cell bottle to a concentration of 1×10 5 / mL, add 1mL cell suspension to each well of a 24-well plate, in CO 2 Place in the cell culture incubator for 24 hours, the culture conditions are 37°C, 5.0% CO 2 concentration.

[0039] c. Dosing: Add 5 μL of the drug solution prepared in the above 1 to each well of 1 to 5 of each row of the 24-well plate, so that the concentration of each compound in each well reaches 80 μg / mL, 40 μg / mL, 20 μg / mL, and 10 μg / mL. mL, 5 μg / mL, add 5 μL DMSO to the sixth well. The final concentration of DMSO in each well was 0.5%. in CO 2 Cell culture incubator, culture conditions 37 ℃, 5.0% CO 2 concentration. Aspirate the supernatant every three days, and re-add the complete medium and drug solution.

[0040] d. Add part of the above cell supernatant ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of sterol and pharmaceutically acceptable salt thereof in preparation of a medicine for treating hepatitis B virus. The sterol comprises at least one of 7-dehydrocholesterol, 5,8-alpha-epidioxy-5alpha-cholest-6-ene-3beta-ol and 5alpha-cholest-7-ene-3beta,5,6beta-triol. The sterol and the pharmaceutically acceptable salt thereof disclosed by the invention have agood anti-hepatitis B virus effect.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to the application of sterols and pharmaceutically acceptable salts thereof in the preparation of anti-hepatitis B virus medicines. Background technique [0002] Hepatitis B virus (HBV) is a typical hepatophagic DNA virus. Chronic infection with HBV will lead to liver fibrosis, cirrhosis, hepatic insufficiency and even liver cancer. Hepatitis B is a chronic necrotic disease caused by hepatitis B virus (HBV) infection, which has become a major public health problem in the world, and the liver cancer caused by it ranks fifth among all malignant tumors. Inhibiting or killing hepatitis B virus plays an extremely important role in the treatment of hepatitis B. [0003] Currently, there are two types of drugs clinically used in the treatment of chronic hepatitis B virus: one is immunomodulators, which have a low response rate and large side effects; the other is nucleotid...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/575A61K31/58A61P31/20A61P1/16C07J9/00C07J71/00
CPCA61K31/575A61K31/58A61P31/20A61P1/16C07J9/00C07J71/0005
Inventor 崔秀灵唐飞许瑞安邵丽丽赫晓林
Owner HUAQIAO UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com